Tuberculosis Clinical Trial
— ECFOfficial title:
A Cluster Randomised Trial to Assess the Impact of an Enhanced Case Finding Strategy on Tuberculosis Notification in The Gambia
Verified date | March 2018 |
Source | London School of Hygiene and Tropical Medicine |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a cluster Tuberculosis (TB) randomized trial in which enhanced case finding (ECF)
strategy will be compared to passive TB case reporting in The Gambia. And that the impact of
ECF on community and household transmission of TB will also be assessed.
The hypothesis is a cluster randomized trial of an enhanced case finding (ECF) strategy will
increase TB case notifications in The Gambia and reduce TB burden in the study area in a cost
effective manner. The impact of ECF on community and household transmission of TB will also
be assessed. The investigators hope this trial will contribute to this evidence base. The
timing alongside a nationwide TB prevalence survey is particularly of benefit as that would
provide a baseline for disease burden against which the investigators may be able to compare
case notification or case detection in selected clusters
Status | Completed |
Enrollment | 650000 |
Est. completion date | October 2015 |
Est. primary completion date | December 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Any newly diagnosed case initiating TB therapy at any of the Gambia Government TB diagnostic and treatment centres in the Greater Banjul Area. - All TB patients are eligible regardless of age, residency, HIV status, or type of TB - All settlements randomised to the intervention arm Exclusion Criteria: - Inability to understand the implications of study participation, whether through cognitive impairment or insurmountable language barrier. - Communities that refuse to accept intervention through decision conveyed by the alkalo and other recognised community leaders |
Country | Name | City | State |
---|---|---|---|
Gambia | Medical Research Council Unit, The Gambia | Fajara, | Near Banjul |
Lead Sponsor | Collaborator |
---|---|
London School of Hygiene and Tropical Medicine |
Gambia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The total number of successive TB cases notified in the intervention area compared to the total number of successive TB cases notified in the control areas | 30 months | ||
Secondary | The total cost of making diagnosis and receiving treatment will be compared between ECF and passive case finding | Residual burden of TB after intervention Proportion of TB detected through ECF vs. passive case finding in intervention areas. Evaluation of diagnostic delay and treatment outcome in cases detected through ECF versus passive case finding |
30 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |